tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2022 Dec 19;10(1)
fac681.
doi: 10.1093/ofid/ofac681. eCollection 2023 Jan.
Influenza Antiviral Use in Patients Hospitalized With Laboratory-Confirmed Influenza in the United States, FluSurv-NET, 2015-2019
Mark W Tenforde[SUP] 1 [/SUP], Charisse N Cummings[SUP] 1 [/SUP], Alissa C O'Halloran[SUP] 1 [/SUP], Gretchen Rothrock[SUP] 2 [/SUP], Pam Daily Kirley[SUP] 2 [/SUP], Nisha B Alden[SUP] 3 [/SUP], James Meek[SUP] 4 5 [/SUP], Kimberly Yousey-Hindes[SUP] 4 5 [/SUP], Kyle P Openo[SUP] 6 7 8 [/SUP], Evan J Anderson[SUP] 6 7 8 [/SUP], Maya L Monroe[SUP] 9 [/SUP], Sue Kim[SUP] 10 [/SUP], Val Tellez Nunez[SUP] 10 [/SUP], Melissa McMahon[SUP] 11 [/SUP], Chelsea McMullen[SUP] 12 [/SUP], Sarah A Khanlian[SUP] 13 [/SUP], Nancy L Spina[SUP] 14 [/SUP], Alison Muse[SUP] 14 [/SUP], Maria A Gaitán[SUP] 15 [/SUP], Christina B Felsen[SUP] 15 [/SUP], Krista Lung[SUP] 16 [/SUP], Eli Shiltz[SUP] 16 [/SUP], Melissa Sutton[SUP] 17 [/SUP], Ann Thomas[SUP] 17 [/SUP], H Keipp Talbot[SUP] 18 [/SUP], William Schaffner[SUP] 18 [/SUP], Andrea Price[SUP] 19 [/SUP], Ryan Chatelain[SUP] 19 [/SUP], Carrie Reed[SUP] 1 [/SUP], Shikha Garg[SUP] 1 [/SUP]
Affiliations
Abstract
From surveillance data of patients hospitalized with laboratory-confirmed influenza in the United States during the 2015-2016 through 2018-2019 seasons, initiation of antiviral treatment increased from 86% to 94%, with increases seen across all age groups. However, 62% started therapy ≥3 days after illness onset, driven by late presentation to care.
Keywords: antiviral; baloxavir; hospital; influenza; oseltamivir; treatment delay.
. 2022 Dec 19;10(1)
fac681.doi: 10.1093/ofid/ofac681. eCollection 2023 Jan.
Influenza Antiviral Use in Patients Hospitalized With Laboratory-Confirmed Influenza in the United States, FluSurv-NET, 2015-2019
Mark W Tenforde[SUP] 1 [/SUP], Charisse N Cummings[SUP] 1 [/SUP], Alissa C O'Halloran[SUP] 1 [/SUP], Gretchen Rothrock[SUP] 2 [/SUP], Pam Daily Kirley[SUP] 2 [/SUP], Nisha B Alden[SUP] 3 [/SUP], James Meek[SUP] 4 5 [/SUP], Kimberly Yousey-Hindes[SUP] 4 5 [/SUP], Kyle P Openo[SUP] 6 7 8 [/SUP], Evan J Anderson[SUP] 6 7 8 [/SUP], Maya L Monroe[SUP] 9 [/SUP], Sue Kim[SUP] 10 [/SUP], Val Tellez Nunez[SUP] 10 [/SUP], Melissa McMahon[SUP] 11 [/SUP], Chelsea McMullen[SUP] 12 [/SUP], Sarah A Khanlian[SUP] 13 [/SUP], Nancy L Spina[SUP] 14 [/SUP], Alison Muse[SUP] 14 [/SUP], Maria A Gaitán[SUP] 15 [/SUP], Christina B Felsen[SUP] 15 [/SUP], Krista Lung[SUP] 16 [/SUP], Eli Shiltz[SUP] 16 [/SUP], Melissa Sutton[SUP] 17 [/SUP], Ann Thomas[SUP] 17 [/SUP], H Keipp Talbot[SUP] 18 [/SUP], William Schaffner[SUP] 18 [/SUP], Andrea Price[SUP] 19 [/SUP], Ryan Chatelain[SUP] 19 [/SUP], Carrie Reed[SUP] 1 [/SUP], Shikha Garg[SUP] 1 [/SUP]
Affiliations
- PMID: 36686630
- PMCID: PMC9846184
- DOI: 10.1093/ofid/ofac681
Abstract
From surveillance data of patients hospitalized with laboratory-confirmed influenza in the United States during the 2015-2016 through 2018-2019 seasons, initiation of antiviral treatment increased from 86% to 94%, with increases seen across all age groups. However, 62% started therapy ≥3 days after illness onset, driven by late presentation to care.
Keywords: antiviral; baloxavir; hospital; influenza; oseltamivir; treatment delay.